2nd Integrin-Targeted Drug Development Summit
August 30 - September 1
Over the last 12 months, the integrins industry has witnessed promising data and clinical updates:
- 7 Hills Pharma’s new study demonstrated integrin activation can bring the heat to cold melanoma tumors and received the FDA’s Fast Track and Orphan Drug designation
- Caladrius Biosciences and Cend Therapeutics presented their alpha-v integrins PhIb/IIa trial data in pancreatic, colorectal and appendiceal cancers
With Corbus Pharmaceuticals paving the way to develop a safe, efficacious integrins-targeted drug to modify disease biology, which will be a game-changer for diseases such as oncology, autoimmune, and ophthalmology, with unmet medical needs.
In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success, including patient selection biomarkers and dosing.
Get your critical questions answered to supercharge your clinical programs, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic, familiar, and rare diseases.
Join us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients.